Immunotherapy drug benefits patients with high-risk local melanomas

An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage IIb and IIc melanoma, according to the results of an international, randomized phase III clinical trial led by UPMC Hillman Cancer Center. These results indicate that this immunotherapy treatment—which currently is approved only for stage III and IV melanomas—may be appropriate for patients with earlier stages of melanoma.

source https://medicalxpress.com/news/2021-09-immunotherapy-drug-benefits-patients-high-risk.html